Samsung Display is accelerating the expansion of its automotive business, one of its next-generation growth engines, by broadening its vehicle OLED portfolio and actively engaging new customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908163344/en/Samsung Display Expands OLED Leadership into Mobility at IAA MOBILITY 2025 The company will be the only panel manufacturer participating in IAA MOBILITY 2025, the world’s largest...
Revealing an exceptional performance across all key financial metrics, Estithmar Holding Q.P.S.C. announced its financial results for the six-month period ended 30 June 2025, following board approval. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730991496/en/Estithmar Holding Reports Record Half-Year Results for 2025 (Graphic: AETOSWire) The company reported revenue of QAR 3.073 billion, an 87% year-on-year increase. Gross prof...
HCLTech, a leading global technology company, today announced a global partnership with Thought Machine, a pioneer in cloud native banking technology, to accelerate the modernization of banks worldwide. The partnership aims to enable banks to rapidly transition from legacy systems and frameworks to intelligent, autonomous financial institutions powered by AI and cloud technologies. Thought Machine’s Vault platform — next-generation core banking and payments technology — will be at the core of...
HTEC, a global digital engineering and product development company, has today announced that it has joined the World Economic Forum’s (WEF) Centre for AI Excellence. HTEC will contribute to the community through its expertise and thought leadership to help advance AI adoption and AI innovation across its core industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911910448/en/HTEC Partners with World Economic Forum to bring A...
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the dosing of the first healthy volunteer in its randomized, double-blind, placebo-controlled, Phase I trial Debio 1453-101 (NCT07035769) ‘A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults’. Debiopharm's Debio ...